Cargando...
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer
OBJECTIVE: Low-grade serous (LGS) ovarian and primary peritoneal cancer is a rare disease with limited therapeutic options. Low response rates are observed with cytotoxic chemotherapy. However, significant responses have been reported in patients treated with bevacizumab. The objective of this study...
Gardado en:
| Publicado en: | Int J Gynecol Cancer |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2014
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4401424/ https://ncbi.nlm.nih.gov/pubmed/24978709 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/IGC.0000000000000190 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|